HUP0103767A3 - Use of estrogen agonist/antagonist for preparation of pharmaceutical compositions available for treating osteoarthritis - Google Patents
Use of estrogen agonist/antagonist for preparation of pharmaceutical compositions available for treating osteoarthritisInfo
- Publication number
- HUP0103767A3 HUP0103767A3 HU0103767A HUP0103767A HUP0103767A3 HU P0103767 A3 HUP0103767 A3 HU P0103767A3 HU 0103767 A HU0103767 A HU 0103767A HU P0103767 A HUP0103767 A HU P0103767A HU P0103767 A3 HUP0103767 A3 HU P0103767A3
- Authority
- HU
- Hungary
- Prior art keywords
- antagonist
- preparation
- pharmaceutical compositions
- estrogen agonist
- treating osteoarthritis
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229940011871 estrogen Drugs 0.000 title 1
- 239000000262 estrogen Substances 0.000 title 1
- 201000008482 osteoarthritis Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23439800P | 2000-09-21 | 2000-09-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0103767A2 HUP0103767A2 (hu) | 2002-12-28 |
| HUP0103767A3 true HUP0103767A3 (en) | 2005-09-28 |
Family
ID=22881216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0103767A HUP0103767A3 (en) | 2000-09-21 | 2001-09-20 | Use of estrogen agonist/antagonist for preparation of pharmaceutical compositions available for treating osteoarthritis |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6777424B2 (hu) |
| EP (1) | EP1192945A3 (hu) |
| JP (1) | JP2002154953A (hu) |
| KR (1) | KR20020023160A (hu) |
| AU (1) | AU778850B2 (hu) |
| CA (1) | CA2357467A1 (hu) |
| HU (1) | HUP0103767A3 (hu) |
| IL (1) | IL145453A (hu) |
| MY (1) | MY136097A (hu) |
| NZ (1) | NZ514306A (hu) |
| ZA (1) | ZA200107725B (hu) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6936072B2 (en) * | 1999-08-18 | 2005-08-30 | Intrinsic Therapeutics, Inc. | Encapsulated intervertebral disc prosthesis and methods of manufacture |
| EP1192945A3 (en) * | 2000-09-21 | 2004-03-03 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating osteoarthritis |
| US20040044226A1 (en) * | 2001-10-15 | 2004-03-04 | Dininno Frank P. | Estrogen receptor modulators |
| RU2355397C2 (ru) * | 2002-06-13 | 2009-05-20 | Уайт | Режимы лечения базедоксифеном |
| MXPA05007771A (es) * | 2003-01-22 | 2005-09-30 | Pfizer Prod Inc | Procedimientos de tratamiento del dolor articular o para mejorar el sueno usando un agonista/antagonista de estrogeno. |
| CN1929835A (zh) * | 2004-01-13 | 2007-03-14 | 惠氏公司 | 芳香酶抑制剂治疗－相关的骨质疏松症的治疗 |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| EA200700243A1 (ru) | 2004-07-14 | 2007-08-31 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы лечения гепатита с |
| AU2005275182A1 (en) | 2004-07-22 | 2006-02-23 | Ptc Therapeutics, Inc. | Thienopyridines for treating Hepatitis C |
| WO2011014516A1 (en) | 2009-07-28 | 2011-02-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Estrogen antagonists as treatments for sclerosing disorders |
| PT2580210T (pt) | 2010-06-10 | 2017-05-31 | Seragon Pharmaceuticals Inc | Moduladores de recetores de estrogénio e suas utilizações |
| US9187460B2 (en) | 2011-12-14 | 2015-11-17 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| US10292971B2 (en) | 2015-10-01 | 2019-05-21 | Olema Pharmaceuticals, Inc. | Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs |
| LT3386500T (lt) | 2015-12-09 | 2022-12-27 | The Board Of Trustees Of The University Of Illinois | Selektyvūs estrogenų receptorių slopintojai benzotiofeno pagrindu |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| RU2019102647A (ru) | 2016-07-01 | 2020-08-03 | Г1 Терапьютикс, Инк. | Антипролиферационные средства на основе пиримидина |
| WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
| AR110728A1 (es) | 2017-01-06 | 2019-04-24 | G1 Therapeutics Inc | Terapia combinada para el tratamiento del cáncer |
| WO2018175670A1 (en) | 2017-03-22 | 2018-09-27 | The Research Foundation For The State University Of New York | Matrix metalloproteinase-9 hemopexin domain inhibitors and methods of treatment using same |
| EA201992768A1 (ru) | 2017-06-29 | 2020-05-19 | Г1 Терапьютикс, Инк. | Морфологические формы g1t38 и способы их получения |
| CN109201730B (zh) * | 2018-09-19 | 2020-08-18 | 浙江工商大学 | 一种乙炔雌二醇降解菌及其修复污染土壤的方法 |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN DEGRADATION |
| JP2023506155A (ja) * | 2019-12-12 | 2023-02-15 | アキュター バイオテクノロジー インコーポレイテッド | エストロゲン受容体分解活性を有する新規クロマン誘導体およびその使用 |
| IL293999A (en) | 2019-12-20 | 2022-08-01 | C4 Therapeutics Inc | Isoindolinone and indazole compounds for degradation of egfr |
| CA3165309A1 (en) | 2020-03-05 | 2021-09-10 | Christopher G. Nasveschuk | Compounds for targeted degradation of brd9 |
| WO2023102381A1 (en) * | 2021-11-30 | 2023-06-08 | Model Medicines, Inc. | Use of pipendoxifene to treat sars-cov-2 infection |
| WO2024030968A1 (en) | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Compounds for modulating ret protein |
| WO2024097989A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein degraders |
| WO2024097980A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992007072A1 (en) * | 1990-10-10 | 1992-04-30 | La Jolla Cancer Research Foundation | Method of inhibiting transcription utilizing nuclear receptors |
| US6004748A (en) * | 1990-10-10 | 1999-12-21 | La Jolla Cancer Research Foundation | Method of inhibiting transcription utilizing nuclear receptors |
| US5118667A (en) | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
| US5407947A (en) * | 1993-11-05 | 1995-04-18 | Eli Lilly And Company | Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans |
| US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
| IL120265A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists |
| IL120270A0 (en) | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to treat osteoporosis |
| US5998402A (en) | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| US5948775A (en) * | 1997-03-19 | 1999-09-07 | American Home Products Corporation | 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones |
| US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| IL152082A0 (en) * | 2000-04-07 | 2003-05-29 | Pfizer Prod Inc | Estrogen agonist/antagonist metabolites |
| ES2394211T3 (es) * | 2000-06-20 | 2013-01-23 | Novartis Ag | Procedimiento de administración de bifosfonatos |
| EP1192945A3 (en) * | 2000-09-21 | 2004-03-03 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating osteoarthritis |
-
2001
- 2001-09-10 EP EP01307667A patent/EP1192945A3/en not_active Ceased
- 2001-09-13 IL IL145453A patent/IL145453A/en not_active IP Right Cessation
- 2001-09-19 ZA ZA200107725A patent/ZA200107725B/xx unknown
- 2001-09-19 MY MYPI20014370A patent/MY136097A/en unknown
- 2001-09-19 CA CA002357467A patent/CA2357467A1/en not_active Abandoned
- 2001-09-19 US US09/956,696 patent/US6777424B2/en not_active Expired - Fee Related
- 2001-09-20 HU HU0103767A patent/HUP0103767A3/hu unknown
- 2001-09-20 NZ NZ514306A patent/NZ514306A/en unknown
- 2001-09-20 AU AU75555/01A patent/AU778850B2/en not_active Ceased
- 2001-09-20 JP JP2001287115A patent/JP2002154953A/ja active Pending
- 2001-09-21 KR KR1020010058719A patent/KR20020023160A/ko not_active Application Discontinuation
-
2004
- 2004-01-22 US US10/762,617 patent/US20040157862A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL145453A (en) | 2008-03-20 |
| IL145453A0 (en) | 2002-06-30 |
| HUP0103767A2 (hu) | 2002-12-28 |
| AU778850B2 (en) | 2004-12-23 |
| EP1192945A2 (en) | 2002-04-03 |
| EP1192945A3 (en) | 2004-03-03 |
| KR20020023160A (ko) | 2002-03-28 |
| AU7555501A (en) | 2002-03-28 |
| US20040157862A1 (en) | 2004-08-12 |
| US6777424B2 (en) | 2004-08-17 |
| MY136097A (en) | 2008-08-29 |
| CA2357467A1 (en) | 2002-03-21 |
| US20020049198A1 (en) | 2002-04-25 |
| ZA200107725B (en) | 2003-03-19 |
| JP2002154953A (ja) | 2002-05-28 |
| NZ514306A (en) | 2003-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0103767A3 (en) | Use of estrogen agonist/antagonist for preparation of pharmaceutical compositions available for treating osteoarthritis | |
| HUP0100120A3 (en) | Pharmaceutical compositions comprising estrogen agonists/antagonists suitable for treating conditions responsive to estrogen | |
| HUP0301346A3 (en) | New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical composition and process for its preparation | |
| HUP0301305A3 (en) | Use of dopamine d2/d3 receptor agonists for preparation of pharmaceutical compositions to treat fibromyalgia | |
| HUP0200264A2 (en) | Use of estrogen agonists/antagonists for producing pharmaceutical compositions suitable for the treatment of cancers | |
| IL153647A0 (en) | Pharmaceutical compositions of estrogenic agents | |
| AP2001002376A0 (en) | Nmda receptor agonist pharmaceutical compositions | |
| HUP0004120A3 (en) | Use of cgmp-pde5 inhibitors for the preparation of pharmaceutical compositions treating neuropathy | |
| AU5945801A (en) | Opoid antagonist compositions and dosage forms | |
| HUP0204229A3 (en) | Compositions oral opioid formulations, compositions process for their preparation and their use | |
| HUP0105021A3 (en) | Compositions having improved delivery of actives and process for their preparation | |
| IL151369A (en) | Use of tgf-beta antagonist for the preparation of pharmaceuticals | |
| EP1177787A3 (en) | Use of an estrogen agonist/antagonist for treating cataracts | |
| HUP0303156A3 (en) | Substituted 2-phenylaminoimidazoline derivatives as ip antagonists, process for their preparation and pharmaceutical compositions containing them | |
| HUP0302130A3 (en) | Combination pharmaceutical compositions and process for their preparation | |
| HUP0300419A3 (en) | Estrogen agonist/antagonist metabolites, pharmaceutical compositions containing them and their use | |
| HUP0105201A3 (en) | The treatment of andropause using pharmaceutical compositions containing estrogen agonists/antagonists and testosterone | |
| HUP0301317A3 (en) | Use of neuroprotective 7-beta-hydroxysteroids for preparation of pharmaceutical compositions | |
| HUP0303731A3 (en) | Sulfonylguanidines and their use for preparation of pharmaceutical compositions | |
| HUP0300389A3 (en) | Crystalline form ii of cabergoline, process for its preparation and pharmaceutical compositions containing it | |
| HUP0204324A3 (en) | Use of fsh for preparation of pharmaceutical composition suitable for treating infertility | |
| HUP0300694A3 (en) | Indole derivatives as mcp-1 receptor antagonists, their use, process for their preparation and pharmaceutical compositions containing them | |
| HUP0201394A3 (en) | Use of pyrrole derivatives for making pharmaceutical compositions | |
| HUP0200311A3 (en) | Use of aroyl- or arylalkanoylpyridazines for preparation of pharmaceutical compositions | |
| HUP0104338A3 (en) | Pharmaceutical compositions containing an estrogen agonist/antagonist as active ingredient for improving vascular health |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |